On July 5th, 2021, Arctic Vision announced a new research collaboration with Prof. Christopher Leung, Head and Clinical Professor at the Department of Ophthalmology of the University of Hong Kong (HKU) for the discovery and development of novel neuroprotective therapies for glaucoma.


Neuroprotection, in the form of non-IOP-related interventions to prevent or delay glaucomatous neurodegeneration, has been underscored to be an unmet need in the management of glaucoma ever since the 2010 World Glaucoma Association Consensus Meeting.[1] However, no neuroprotective therapy has been approved for the treatment of glaucoma to date. This ground-breaking collaboration between Arctic Vision and HKU to discover new therapies with novel mechanisms of action marks a paradigm shift of the global research approaches to treatment of glaucoma.


This project has three main objectives:

-        Modulate mitochondrial activity as a neuroprotective strategy for glaucoma;

-        Develop a microRNA-based gene therapy for protection of optic nerve in glaucoma patients;

-        Reprogram cellular pathways for neuroprotection and neuro-regeneration in RGCs.


Arctic Vision will sponsor this four-year collaboration, which will include the development of in vivo experimental glaucoma models and a Phase 1 clinical trial.


Suite 906-908, 9F, Tower II, Century Link, 1196 Century Avenue, Shanghai, China
Copyright © 2020 Arctic Vision (Shanghai) Biotechnology Co., Ltd.